To include your compound in the COVID-19 Resource Center, submit it here.

bluebird reports updated data for bb2121 CAR T in MM

bluebird bio Inc. (NASDAQ:BLUE) reported updated data from the Phase I CRB-401 trial evaluating its chimeric antigen receptor (CAR) T cell therapy bb2121 in patients with relapsed or refractory multiple myeloma (MM). Data were presented

Read the full 358 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE